Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Notification

AWMSG November medicines approvals

The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Xultophy (insulin degludec and liraglutide) for use with oral antidiabetic drugs to treat adults with type 2 diabetes — it can only be used when oral treatments combined with basal insulin do not provide adequate glycaemic control; Fomicyt (fosfomycin) to treat acute osteomyelitis, complicated urinary tract infections, nosocomial lower respiratory tract infections or bacterial meningitis, or any bacteraemia believed to be associated with these infection — it should only be used when common treatments for these infections are inappropriate or have shown to be ineffective; Travatan (travoprost) for paediatric patients with ocular hypertension or paediatric glaucoma; Bramox (midodrine hydrochloride) to treat severe orthostatic hypotension due to autonomic dysfunction. The AWMSG website has the full details of restrictions.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200135

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.